Biodexa Pharmaceuticals Plc

Snapshot

Biodexa is a clinical-stage biotech with no meaningful revenue, a $8.4M net loss in FY 2025, and cash of $11.5M against a burn rate that leaves only about 14 months of runway.

What's Happening Right Now

• Tue 1st Sep '26 · Dilution overhang: A filing registers resale of shares tied to warrants from a July 2026 raise, described as a significant overhang versus the public float, and cites a going-concern warning from auditors.
• Wed 19th Aug '26 · Trial progress: Biodexa passed the halfway point in recruitment for its Phase 3 Serenta trial in familial adenomatous polyposis, with 87 of 168 planned subjects enrolled.
• Tue 18th Aug '26 · Reverse split: Shareholders approved a drastic 1-for-10,000 reverse split effective July 30, 2026, undertaken to satisfy Nasdaq's minimum bid price requirement.
• Wed 1st Jul '26 · Dilutive raise: A $3.5 million financing priced shares at a steep discount to net tangible book value, expected to cut per-share book value by more than half.
• Mon 29th Jun '26 · Trial expansion: Health Canada approved expansion of the Serenta Phase 3 trial into Canada, adding to the 29 active recruiting sites across the US and Europe.